The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study

BACKGROUND: Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X. Although it reduces the frequency of bleeding episodes, there is still need for bypassing agents in case of breakthrough bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Nina Haagenrud, Glosli, Heidi, Bjørnsen, Stine, Holme, Pål Andre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Replication Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268661/
https://www.ncbi.nlm.nih.gov/pubmed/34263107
http://dx.doi.org/10.1002/rth2.12561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268661/
https://www.ncbi.nlm.nih.gov/pubmed/34263107
http://dx.doi.org/10.1002/rth2.12561

Ejemplares similares